Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
87.7M
-
Number of holders
-
42
-
Total 13F shares, excl. options
-
16.8M
-
Shares change
-
-386K
-
Total reported value, excl. options
-
$49.9M
-
Value change
-
-$1.4M
-
Number of buys
-
15
-
Number of sells
-
-16
-
Price
-
$2.97
Significant Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) as of Q1 2022
44 filings reported holding TERN - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q1 2022.
Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) has 42 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.8M shares
of 87.7M outstanding shares and own 19.16% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (3.79M shares), Vivo Capital, LLC (2.68M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.35M shares), FMR LLC (2.32M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.24M shares), Antara Capital LP (1.07M shares), BlackRock Inc. (737K shares), Decheng Capital Management III (Cayman), LLC (714K shares), VANGUARD GROUP INC (433K shares), and Samsara BioCapital, LLC (289K shares).
This table shows the top 42 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.